Senescence in osteoarthritis: from mechanism to potential treatment

Yikai Liu, Zian Zhang, Tao Li, Hao Xu and Haining Zhang*

Abstract
Osteoarthritis (OA) is an age-related cartilage degenerative disease, and chondrocyte senescence has been extensively studied in recent years. Increased numbers of senescent chondrocytes are found in OA cartilage. Selective clearance of senescent chondrocytes in a post-traumatic osteoarthritis (PTOA) mouse model ameliorated OA development, while intraarticular injection of senescent cells induced mouse OA. However, the means and extent to which senescence affects OA remain unclear. Here, we review the latent mechanism of senescence in OA and propose potential therapeutic methods to target OA-related senescence, with an emphasis on immunotherapies. Natural killer (NK) cells participate in the elimination of senescent cells in multiple organs. A relatively comprehensive discussion is presented in that section. Risk factors for OA are ageing, obesity, metabolic disorders and mechanical overload. Determining the relationship between known risk factors and senescence will help elucidate OA pathogenesis and identify optimal treatments.

Keywords: Osteoarthritis, Cellular senescence, Immunotherapy, Killer cells, Natural, SASP (senescence-associated secretory phenotype)

Introduction
Osteoarthritis (OA) is the most common joint disease worldwide and imposes substantial mental and physical burdens on elderly individuals. Nearly 250 million people suffer from OA, making it a leading cause of disability in the elderly population [1]. As a degenerative disease, cellular senescence has been proposed to be involved in OA [2]. Cellular senescence is a cell state characterized by permanent cell cycle arrest, resistance to apoptosis, and the continuous secretion of senescence-associated secretory phenotype (SASP) factors [3]. In OA, SASP factors are referred to as a group of inflammatory factors, such as cytokines, chemokines and enzymes. SASP factors are a general name of these inflammatory factors from the perspective of senescence.

Chondrocyte senescence was identified in tissues from human OA patients many years ago, and senescent chondrocytes were shown to accumulate with age in articular cartilage [2]. Recently, there has been renewed interest in studying senescence from a mechanistic angle using OA mouse models, and many senolytic drugs have been studied as a therapeutic approach [4, 5]. Several molecules were found to be pivotal in OA-related senescence, such as GATA [6], STING [7], FOXD1 [8], SIRT6 [9] and DGCR8 [10]. In addition to senescent chondrocytes, senescent fibroblast-like synoviocytes in the osteoarthritic joint also promote OA progression [6]. Synovial fibroblasts, synovial macrophages, osteoblasts and adipocytes are involved in the production of SASPs in addition to chondrocytes during ageing [11]. The inflammatory environment induced by SASP factors is involved in cartilage degeneration and subchondral bone remodelling and eventually leads to cartilage loss and OA progression. Unlike rheumatoid arthritis (RA), OA was first considered a disease associated with wear and tear of joint cartilage rather than inflammation. However, OA has been
treated as a combination of injury and inflammation in recent decades, as mounting evidence has revealed the significant role of cytokines and immune cells in the pathology of OA [12–15].

Although the specific mechanism of cellular senescence in OA is unclear, the selective clearance of senescent cells in osteoarthritic mice can attenuate the development of post-traumatic OA (PTOA) [16], while intraarticular injection of senescent cells induced mouse OA [17]. Eliminating p16INK4A-positive cells in various organs attenuated age-related deterioration without obvious side effects [18]. The clearance of senescent cells has also been shown to be effective in tau-dependent pathology and cognitive decline-associated diseases [19]. These striking results aroused interest in exploring the underlying mechanism of senescence and its therapeutic targets.

Natural killer (NK) cells play a vital role in the surveillance and killing of senescent cells. Manipulating NK cells to restore the balance between young and senescent cells is promising in age-related diseases. However, whether NK cells function in the senescence environment of osteoarthritic joints remains largely unknown.

The senescent microenvironment in the osteoarthritic joint includes not only senescent chondrocytes, but also synovial fibroblasts and synovial macrophages [11]. Although the senescence of these cells in the joint cavity plays an important role in the pathogenesis of OA, we mainly focused on senescent chondrocytes because chondrocytes are the only cells in cartilage and determine the homeostasis of anabolism and catabolism of the osteoarthritic cartilage matrix. In addition, the senescence of other cells in the joint should never be ignored. In fact, most antisenescence drugs at present are not aimed at a single senescent cell type. Here, we systematically review senescence in OA and propose some ideas for treatment optimization.

Regulatory factors and characteristics of senescence and the SASP

The mechanisms leading to senescence are numerous and complicated. DNA damage can induce the DNA damage response (DDR), leading to the direct activation of p53 and its downstream transcription factor p21. Increasing levels of reactive oxygen species (ROS) in the cytoplasm can activate p16, p53 and p21 via the MKK3/6-p38MAPK pathway [20–22]. SASP factors, such as TGF-β and IL-6, can activate p21, p27 and p15 and promote senescence via the SMAD complex or STAT3 pathway, respectively [23–25]. Oncogenic signalling and tumour suppressor inactivation can induce DDR through RAS, Myc and PI3K, resulting in the activation of p53 and p21 [26, 27]. Among these transcription factors, p21 inhibits CDK2, and p16INK4A inhibits CDK4/6 [28, 29]. Then, Rb hypophosphorylation is sustained, and Rb binds with the transcription factors E2F and DP as a result of CDK2/4/6 inhibition. Due to the reduction in E2F and DP, S-phase entry is blocked, followed by cell cycle arrest [4, 21] (Fig. 1).

Although both permanent cell cycle arrest and continuing secretion of SASP factors are characteristics of senescence, these processes have different but overlapping mechanisms. It has been suggested that the production and secretion of SASP factors are independent of cell

![Fig. 1 Signalling mechanisms leading to senescence. Mechanical stress, DNA damage, ROS, oxidative stress and other adverse conditions induce cellular senescence. p53-p21-CDK2 and p16-CDK4/6 are two pathways involved in senescence. CDK2/4/6 inhibit RB and promote S phase entry, leading to cell cycle arrest and cellular senescence. ROS, reactive oxygen species; CDK, cyclin-dependent kinases; RB, retinoblastoma protein](image-url)
cycle arrest, as p16\textsuperscript{INK4A} knockout mouse chondrocytes do not decrease the release of SASP factors [30].

The production of SASP factors is associated with NF-κB, p38MAPK and mTOR. SASP can be regulated at different levels from transcription to secretion [31]. The NF-κB pathway is an inflammatory pathway that is involved in the transcription of multiple inflammatory factors [32]. NF-κB is considered a major signalling pathway that stimulates SASP factor production [33]. p38MAPK is induced by stress and is also induced in different types of senescent fibroblasts. p38MAPK inhibition can reduce most SASP factors to a large extent [34]. p38MAPK itself is sufficient to induce the SASP, and this effect is independent of the DDR, promoting long-term SASP factor secretion. Mechanistically, p38MAPK induces SASP by enriching the abundance of SASP factor mRNA and controlling the activity of NF-κB [34]. Rapamycin, an inhibitor of mTOR, can modulate the production of SASP factors by suppressing membrane-bound IL-1α translation and decreasing NF-κB activity [35]. In addition, mTOR regulates the translation of MAPKAPK2, which is also referred to as MK2. MAPKAPK2 phosphorylates and inhibits ZFP36L1, a zinc-finger protein that can degrade the transcripts of SASP factors. Therefore, mTOR is involved in stabilizing SASP components [36].

These SASP factors have upstream and downstream relationships. IL-1α on the cell membrane can enhance the binding ability of NF-κB and C/EBPβ to DNA and then stimulate the transcription of IL-6 and IL-8 [37]. Typical SASP factors, such as IL-6 and IL-8, can enhance SASP factor secretion in turn to form a feed forward loop, thus reinforcing senescence [38].

Early SASP factors, such as TGFβ, can also stimulate normal cells to become senescent cells, leading to the expansion of senescence [39, 40]. Later, SASP factors exert robust abilities to recruit immune cells and exacerbate the inflammatory environment. The switch in SASP is mediated by NOTCH1 [41].

**Possible mechanisms leading to senescence in OA**

**Overload and mechanical stress**

Mechanical overloading promoted senescence in vitro in cultured chondrocytes and in mouse cartilage [42]. Reduced F-box and WD repeat domain containing 7 (FBXW7) was detected in osteoarthritic patient cartilage, osteoarthritic mouse cartilage, aged mouse cartilage and in vitro cultured primary chondrocytes undergoing mechanical loading. FBXW7 deficiency in chondrocytes induced chondrocyte senescence and promoted cartilage catabolism in mice [42]. Mechanical overloading accelerated chondrocyte senescence by reducing FBXW7 expression and FBXW7-dependent MKK7 degradation, which subsequently stimulated JNK signalling [42].

Inhibition of JNK activity by DTP3 ameliorated chondrocyte senescence and cartilage degeneration, which suggested a harmful effect of JNK activation in osteoarthritic chondrocytes [42]. However, another study suggested JNK deletion enhanced p16 expression in the synovium and cartilage in older mice and promoted age-related OA, indicating that JNK may be a negative senescence regulator in the joint [43]. Mechanical overload is responsible for generating ROS and affects joint degeneration and remodelling [44]. Piezo1 is an ion channel that mediates mechanosensory transduction [45].

Mechanical stretching can induce Ca\textsuperscript{2+} influx via Piezo1, triggering the activation of multiple pathways [46]. The transient receptor potential vanilloid 4 (TRPV4) ion channel is a Ca\textsuperscript{2+} channel, which was first recognized as a transducer of osmotic stress [47, 48]. TRPV4-mediated Ca\textsuperscript{2+} signalling in response to osmotic fluctuations in the cartilage is a potential mechanism by which chondrocytes sense and respond to joint loading [49]. One recent study revealed that a dysfunctional TRPV4-GSK3β pathway prevented osteoarthritic chondrocytes from sensing changes in extracellular matrix viscoelasticity [50]. Excessive mechanical stress induced chondrocyte apoptosis through TRPV4 in an anterior cruciate ligament-transected rat OA model [51]. These findings stressed the importance of TRPV4 in sensing mechanical stress. Other findings indicate that TRPV4 could be a modulated channel in chondrocytes and synovial cells that interacts with proinflammatory factors and mediates inflammatory signalling and mechanical stress [52, 53]. The activation of Piezo1 and TRPV4 leads to Ca\textsuperscript{2+} influx, Ca\textsuperscript{2+} overload in the cytoplasm, mitochondrial dysfunction and the accumulation of ROS. Then, the DDR occurs, the cell cycle arrest and senescence develops [21, 54]. Moreover, mechanical stress can induce mitochondrial dysfunction through multiple pathways [55]. Gremlin-1 was identified as a mechanical loading-inducible factor in osteoarthritic chondrocytes. A high level of gremlin-1 was detected in middle and deep layers of cartilage after cyclic strain or hydrostatic pressure loading [56]. Mechanistically, gremlin-1 promoted OA progression by activating NF-κB signalling and elevating catabolic enzymes [56] (Fig. 2).

**Inflammatory microenvironment**

There is an age-related proinflammatory state termed “inflamm-aging”. Age-related inflammation can be both systemic and local [57]. Senescent cells produce SASP factors, which promote the inflammatory microenvironment and cartilage catabolism. Chemokines such as CCL2 and CCL4 can recruit macrophages and NK cells [58]. Cytokines such as IL-1, IL-6, IL-7, IL-8, IL-17, OSM, GM-CSF and TNF are involved in OA progression
Proteases such as MMP1, MMP3, MMP10, MMP13 and ADAMTS5 can degrade cartilage extracellular matrix (ECM) and promote OA pathology [61, 62]. Growth factors such as TGF-β are involved in the formation of osteophytes [63]. The production of SASPs is not only a characteristic of senescent chondrocytes. Adipocytes, osteoblasts, synovial fibroblasts, synovial macrophages and NK cells in joints are also crucial [11]. In fact, 55% of cytokines are produced by synovial cells, and synoviocyte-chondrocyte interactions play a vital role in the pathogenesis of OA [64].

In addition, senescent cells can release SASPs into their surroundings, which exerts a chemotactic effect on immune cells. The inflammatory microenvironment established by immune cells and the SASP are thought to drive cartilage degeneration by degrading ECM. Few cartilage fragments and other ECM degrading products can induce inflammation. For example, lumican, a major extracellular matrix glycoprotein, is upregulated in osteoarthritic cartilage and synovial fluid (SF). Lumican in SF exacerbates proinflammatory activation induced by TLR4 and leads to macrophage polarization [65].

Moreover, this senescent microenvironment hampers the repair of cartilage by bone marrow stem cells (BMSCs). In vitro coculture assays indicated that senescent chondrocytes and BMSCs interacted with each other. Senescent chondrocytes inhibited proliferation, facilitated senescence, and suppressed chondrogenic differentiation of BMSCs. BMSCs induced the apoptosis of senescent chondrocytes and reduced the proportion of senescent chondrocytes. The intra-articular senescent microenvironment caused by senescent cells and the SASP inhibited the repair of damaged cartilage by BMSCs [66].

**Oxidative stress**
Mechanical stress and ageing are two main risk factors for OA, both of which are capable of producing ROS and oxidative stress [44, 67]. Mitochondrial dysfunction...
and oxidative stress are key factors in OA [67]. mtDNA damage is one possible reason leading to the senescence of osteoarthritic chondrocytes, which may be attributed to increasing mitochondrial ROS production and shortening of telomeres under stress conditions [68]. Poor repair of mtDNAs caused by oxidative stress is thought to be associated with OA pathogenesis [69]. ROS promote mitochondrial dysfunction, induce DNA damage and DDR and lead to premature senescence, matrix degradation and subchondral bone mass loss in OA [70]. Oxidative stress results in membrane and nucleic acid damage, as well as the degradation of extracellular components and cartilage destruction. ROS inhibit the synthesis of proteoglycans by NO in the cartilage, and H2O2 inhibits proteoglycan synthesis by forming ATP and suppressing mitochondrial oxidative phosphorylation [71, 72].

Increased mitochondrial superoxide and decreased SOD2 were induced in chondrocytes under mechanical stress conditions, and the loss of SOD2 led to mitochondrial superoxide accumulation. This imbalance in antioxidants and prooxidants is related to cartilage degeneration [73]. Decreased levels of antioxidant enzymes are associated with accelerated senescence or premature senility, as SOD2−/− mice exhibit decreased lifespans, accelerated ageing cellular phenotypes, and increased p16 and p21 at both the mRNA and protein levels [74]. SOD2 deletion leads to severe OA, while SOD2 overexpression or the use of antioxidants reduces OA [75]. Peroxiredoxins participate in the clearance of excess H2O2 and act as antioxidants [75, 76]. Under oxidative stress, peroxiredoxins are hyperoxidized and inactivated, which attenuates survival signalling by inhibiting the Akt signalling pathway and promoting p38 signalling in chondrocytes [76]. These studies indicate the negative influences of ROS on cartilage.

Oxidative stress also activates the NF-κB pathway and promotes MMP overproduction, thus triggering DNA damage and cell senescence [77]. Upon exposure to oxidative stress, redox-sensitive PKCδ activates IKKα and triggers its translocation to the nucleus, resulting in phosphorylation and activation p53 [78]. p53 modulates the DDR and orchestrates homeostatic activities and dysfunctional responses, such as irreversible cell cycle arrest and cellular senescence [79].

Inflammation and oxidative stress intensify one other and damage the cartilage [77]. ROS play an important role in the production of SASP components, including IL-1, IL-6 and MMPs [80]. Inflammatory changes decreased the level of antioxidant enzymes in biological fluids and cartilage and increased the level of oxidative agents, which hampered cartilage matrix proteins and led to cartilage damage [77, 81].

**Metabolism and energy shortage**

Metabolism is substantially changed and abnormal immunometabolism plays a pivotal role in OA [82]. Obesity is an influential risk factor for OA, and it affects not only the abnormal mechanical stress on joints but also metabolic changes [83, 84]. High body mass index (BMI) was related to hand and knee OA but not hip OA in a 10-year follow-up study [85], which indicates that there must be metabolic abnormalities contributing to OA.

Individuals with obesity show high levels of TNF-α, IL-1β and IL-6 in serum, and these SASP factors are produced by macrophages in adipose tissue [83]. Adipokine and other obesity-associated metabolic factors can induce the expression of proinflammatory cytokines and degradative enzymes, exacerbating cartilage damage and subchondral bone remodelling [84]. Moreover, high levels of adipokines influence M1 macrophage polarization [86], which is considered a proinflammatory phenotype. Free fatty acids (FFAs) increase oxidative stress levels along with increased IL-6 and IL-8 secretion [87]. Leptin induces MMP1, MMP3 and MMP13 expression in chondrocytes [88] and induces chondrocyte senescence by activating the p53/p21 pathways and suppressing sirtuin 1 (SIRT1) [89]. Overall, metabolic syndrome can affect OA development directly by stimulating proinflammatory and catabolic factors and indirectly by interfering with autophagy and senescence (Fig. 3).

Sirtuins (SIRTs) help cells adapt their energy output to match energy requirements by sensing the NAD+ concentration in the cytoplasm [90]. The correlation between SIRT and senescence has been verified in many age-related diseases, such as Alzheimer’s disease [91] and diabetes mellitus [92]. SIRTs, especially SIRT1, SIRT3 and SIRT6, exert antiaging effects through various pathways and exhibit connections with mTOR, PI3K, AMPK and NF-κB [93, 94].

In directly cartilage, SIRT1 has been studied most thoroughly, and increasing studies have identified the importance of SIRT6 [95]. SIRT1 conditional knockout mice exhibit accelerated OA progression and are more vulnerable to ageing and mechanical stress stimulation [96, 97]. In addition, SIRT1 interacts with the cartilage-specific transcription factor Sox9 and promoted collagen 2 transcription. SIRT1 and NAD may benefit cartilage by upregulating genes encoding cartilage ECM components [98]. SIRT1 is cleaved to form an inactive N-terminal (NT) polypeptide and a C-terminal (CT) fragment in chondrocytes under proinflammatory stress, and the serum NT/CT SIRT1 ratio is an indicator of early OA and chondrosenescence [99]. Moreover, SIRT1 is related to circadian rhythm, as inhibiting SIRT1 leads to a reduction in the clock gene Bmal1 [100], which is associated
with cartilage damage and circadian rhythm disturbances [96] (Fig. 3).

SIRT3 is mainly located in mitochondria and can maintain mitochondrial function, regeneration and dynamics through its deacetylase activity [101]. A recent study proposed that SIRT3-mediated mitochondrial homeostasis protected against OA development [101]. SOD2 is a protective factor against oxidative stress, and SOD2-specific activity decreased with age in mouse chondrocytes due to elevated post-translational lysine acetylation. SOD2 acetylation was also detected in osteoarthritic chondrocytes. SIRT3 is involved in the deacetylation of SOD2, increasing SOD2-specific activity and protecting against OA progression [102] (Fig. 3).

The loss of SIRT6 can increase DNA damage and telomere dysfunction and increase SA-β-Gal-positive chondrocytes and p16 and γH2AX foci, thus inducing premature senescence [9, 103]. SIRT6 overexpression inhibited replicative senescence. Decreased levels of SIRT6 were found in osteoarthritic patient cartilage compared to that of healthy individuals, while overexpression of SIRT6 in a mouse knee OA model retarded OA progression by alleviating the inflammatory response and chondrocyte senescence [104]. IL-1β lowered the expression of SIRT6 and increased the expression of MMP13, and the upregulation of MMP13 could be reversed by overexpressing SIRT6. Further experiments revealed decreased expression of NF-κB but no change in p65 nuclear translocation after SIRT6 overexpression, which established connections between inflammatory pathways and SIRT6 [105]. In addition, these studies indicate that specific activators of SIRT6 may be potential therapeutic targets for controlling senescence and ameliorating OA development (Fig. 3).

**Autophagy**

Autophagy usually occurs when cells are under stressful conditions. Damaged and dysfunctional organelles and proteins are engulfed and degraded by lysosomes to save energy under stress conditions, such as nutrient deprivation, hypoxia, ROS and DNA damage [106, 107]. The expression of ULK1, LC3 and Beclin1 in normal human articular cartilage suggests that autophagy is constitutively active in chondrocytes [108], and avascular
and hypoxic conditions in cartilage may account for this activation. Autophagy seems to protect chondrocytes against cell death, as both human osteoarthritic chondrocytes and surgery-induced OA mouse models showed decreased ULK1, Beclin1 and LC3 levels and increased apoptosis [108]. In addition, old mice showed reduced autophagic vesicles and decreased levels of ATG-5 and LC3 in knee articular cartilage compared with young mice, with increased levels of the apoptosis marker p85 [109]. Regulated in development and DNA damage response 1 (REDD1), an endogenous inhibitor of mTOR, was protective in the OA model, which suggested the benefit of autophagy in chondrocytes [110]. However, another study noted the dual effects of autophagy on cartilage: in normal human cartilage, autophagy is cytotoxic, and in osteoarthritic cartilage, autophagy promotes death [111].

Autophagy can regulate senescence by controlling protein degradation. Chaperone-mediated autophagy (CMA) accounts for the majority of the lysosome-autophagy proteolytic system [112]. Deficient CMA results in the accumulation of misfolded proteins and oxidative products, and this dysregulation of proteostasis ultimately leads to senescence [112]. In addition, DNA damage promotes senescence by reducing autophagy of GATA4 [113]. The transcription factor GATA4 was identified as a regulator of senescence and the SASP; as it promotes senescence by activating NF-κB and initiating SASP factor production. GATA4 is degraded by p62-mediated selective autophagy under normal conditions, and this process is reduced when senescence occurs [113].

Targeting senescence by controlling autophagy needs further investigation. First, autophagy may partly control some but not all senescence processes. Although rapamycin-mediated inhibition of mTOR prevents SASP induction [36], it fails to prevent or reverse the cell cycle arrest caused by oncogenic RAS [35]. Second, autophagy may be a double-edged sword in senescence; in other words, whether autophagy is beneficial or harmful in osteoarthritic cartilage remains contradictory [114]. Sustained p53 activation occurs even senescent cells are in cell cycle arrest, and activated p53 can induce the transcription of several autophagy-associated proteins such as ULK1, ATG5 and ATG7 [114]. These studies indicated that autophagy may be constitutively activated during senescence. One recent study noted that autophagy leads to senescence via mTORC2 [115]. Autophagic fibroblasts express p16 and p21 and are SA-β-Gal-positive. Suppressing or silencing mTORC2 activation prevents senescent hallmarks [115]. Whether autophagy promotes senescence or protects against senescence should be determined before autophagy-regulating drugs are used to control senescence.

### Therapeutic targeting of senescence

**Drugs that eliminate senescence**

Drugs can be roughly divided into two groups: senolytics and senomorphics. The former aims to kill senescent cells, while the latter neutralizes the SASP and offsets its effects. Different molecular targets have been developed.

Senolytics have been proven to improve physical function and increase lifespan in mice [116]. Several senolytics have been developed. Dasatinib targets BCR-ABL, SRC, c-KIT and the ephrin A receptor. Quercetin targets PI3K and serpins. Fisetin targets SIRT1 and IL-1β [117]. UBX0101 targets MDM2, and navitoclax (ABT-263) targets BCL-2 and BCL-XL [118]. Some of these agents are proapoptotic drugs and have been used in cancer treatment. Inducing apoptosis helps to reverse senescence and leads to cell death. Senomorphics, such as lutikumab and canakinumab, target IL-1β; tocilizumab targets IL-6 receptors, etanercept targets TNF and CL82198 targets MMP13 [4, 63].

Intraarticular injection of quercetin ameliorated cartilage degradation and chondrocyte apoptosis. Reduced intracellular ROS, restored mitochondrial membrane potential and an inhibited Caspase-3 pathway were observed in rat chondrocytes after application of quercetin. In addition, increased M2 polarization, TGF-β and IGF created a pro-chondrogenic microenvironment for cartilage repair [119]. UBX0101 showed encouraging effects in treating an ACLT-induced mouse OA model, regardless of early or later OA stage, in young or old individuals [16]. However, compared to placebo, UBX0101 resulted in no differences in WOMAC-A scores in a 183-person phase II clinical trial of OA (NCT04129944), and a dose–response relationship was not observed. In fact, only the lowest dose showed a curative effect. Fisetin, a flavonoid with potential anti-inflammatory and senolytic functions [117, 120], has been proven to alleviate joint damage in the destabilization of the medial meniscus (DMM) model and is also under investigation in knee OA in a phase I–II clinical trial (NCT 04,210,986).

In addition to senolytic drugs, which aim to kill senescent cells, senomorphic drugs directly inhibit or neutralize SASP factors. IL-1 plays a vital role in cartilage degradation and OA development and has been an attractive target in OA for many years. Mechanistically, IL-1 induces the transcription of MMP13 and ADAMTS5 and is involved in their bioavailability [121]. However, multiple methods to suppress IL-1 did not show satisfactory outcomes in numerous preclinical and clinical studies, including the application of IL-1 receptor antagonist proteins, soluble IL-1 receptors, monoclonal antibodies against IL-1 or against the IL-1 receptor, blocking the formation of active IL-1β, blocking IL-1...
signalling pathways and gene therapy [122]. The MMP-13 inhibitor PG-116800 failed in a randomized, double-blind, placebo-controlled, multicentre, parallel-group, dose–response study of treating knee OA, with no clear benefit in relieving pain and improving function [123]. Th17 cells play roles in ankylosing spondylitis, and psoriatic arthritis and various biologic agents, such as IL-17 antibodies, have been developed [124]. One recent study [125] focused on IL-17 and found that a type 17 immune response was induced in joint and draining inguinal lymph nodes after ACLT administration. In vitro experiments demonstrated that Th17 cells induced senescence in fibroblasts. Intraarticular injection of an IL-17-neutralizing antibody in mice alleviated cartilage degeneration and the senescence marker p21 [125]. These results provide evidence of the roles of IL-17 and Th17 cells in OA development and cartilage senescence. However, increased IL-17 mRNA was detected in RA synovial tissue but barely in OA [126]. Whether IL-17 antibodies or other biological agents are useful in humans remains to be tested.

Metformin was recently reported to have effects other than reducing blood sugar, such as attenuating ageing via numerous mechanisms [127]. Activating AMPK and SIRT1, reducing mTORC1, inhibiting NF-κB and inflammatory pathways, regulating the gut microbiota, improving metabolism, prohibiting DNA damage, promoting DNA repair and reducing telomere shortening were involved in the effects of metformin against senescence [127]. One recent study revealed that metformin restricted OA progression through the activation of AMPK signalling [128]. Metformin prevented the formation of osteoclasts, inhibited bone absorption and abnormal subchondral bone remodelling and alleviated OA via the AMPK/NF-κB/ERK signaling pathway [129]. Metformin alleviates monosodium-iidoacetate-induced OA by regulating pain mediators and autophagy [130]. Metformin is promising for controlling senescence and treating OA.

Some senomorphics are under investigation in clinical trials; for examples, tanezumab (NCT02528188) and fasinumab (NCT02683239, NCT03161093, NCT03304379) are NGF inhibitors and are in phase III clinical trials of hip or knee OA. Tocilizumab, an IL-6R inhibitor, is in a phase III clinical trial of hand OA (NCT02477059). The ADAMTS5 inhibitors, GLPG1972/S201086 and M6495, were investigated in phase II clinical trials (NCT03595618) and phase I clinical trials (NCT03583346) of knee OA, respectively. GSK3858279, a CCL17 inhibitor, is in a phase I clinical trial of knee OA (NCT03583346). Otilimab, a GM-CSF inhibitor, is in a phase II clinical trial of hand OA (NCT02683785).

Many questions must be taken into consideration when using senolytics or senomorphics in OA. First, senescence exerts a beneficial effect on wound healing [131, 132] and tumour suppression [133]. Inducing senescence in tumour cells helps the immune system target tumours. The senescent microenvironment produced by senescent cells and the SASP also prohibits tumour progression [134]. Long-term senescent cells may cause chronic inflammation and damage cartilage, but the acute phase of senescence may be useful in ameliorating injury [4, 135]. In addition, there may be off-target effects of senolysis; in other words, these agents do not kill senescent cells specifically. Several chemotherapeutics exhibited effects on total body cells with high proliferative properties. For instance, systemic side effects restrict the use of senolytics for kidney fibrosis [136].

miRNAs controlling senescence
MicroRNAs (miRNAs) are small noncoding RNAs that can bind to the 3′-untranslated region (3′-UTR) of target mRNAs, inhibit translation and lead to target mRNA degradation. miRNAs play important roles in cellular senescence induced by oxidative stress [137–139]. miRNAs can be a component of exosomes, which are secreted into the ECM and affect other cells in a paracrine manner [138]. Mounting evidence suggests that non-coding RNAs participate in the regulation of SASP factor production at the transcriptional level [140].

As two downstream products of NF-κB, miR-302b and miR-146a exert negative feedback effects on the NF-κB pathway [141]; they inhibit the NF-κB pathway and SASP production by participating in the degradation of the IRAK4 and TRAF6 transcripts, respectively [141, 142]. Notably, miR-140 attenuates early OA development by inhibiting chondrocyte senescence [143]. Insulin-like growth factor 1 receptor (IGF1R) and Toll-like receptor 4 (TLR4) in the PI3K-AKT pathway and JAG1 and NUMBL in the Notch pathway are targets of miR-140 [143]. miR-204 is induced by the transcription factors GATA4 and NF-κB under stress conditions and governs the senescent phenotypes of chondrocytes [144]. miR-204 inhibits various components of proteoglycan (PG) biosynthesis, leading to loss of cartilage and OA development [144]. Inhibiting miR-204 restored PG synthesis, suppressed SASP factor secretion and ameliorated OA in a mouse model [144]. miR-34a affects chondrocyte proliferation, senescence and apoptosis, as reported in another study [145]. miR-34a inhibits SIRT1 expression directly, thus reducing the deacetylation of p53 and promoting senescence, increasing Bax and decreasing Bcl2 [145]. Intraarticular injection of lentivirus containing the anti-miR-34a sequence slowed the progression of OA [145].
Some miRNAs show antiaging effects in other cells. miR-290 acts as a physiological effector of senescence in mouse embryonic fibroblasts [146]. miR-22 induces cellular senescence and acts as a tumour suppressor by directly targeting CDK6, SIRT1 and Sp1 [147]. Overexpression of miR-302, miR-512-3p and miR-515-3p can rescue Ras(G12V)-induced senescence by inhibiting p21 [148]. miRNAs associated with senescence and OA are listed in Table 1.

**Immunotherapy against senescence**

Compared with drugs that kill senescent cells, the clearance of senescent cells by the immune system seems to be a more selective and more natural method. Some specific epitopes on the cell membrane or the SASP, as well as abnormally expressed proteins, have been found. However, not all of these epitopes are eligible to be treated as targets. For example, p16INK4A, a widely used biomarker of senescent cells, was not suitable as a target, as silencing p16 in adult mouse chondrocytes did not decrease the SASP, nor did it change the rate at which OA occurred in response to physiological ageing or induced joint abrasion. Senescence affects the pathology of OA largely in a SASP-dependent manner, not through the cell cycle arrest itself [30].

Accumulated and activated CD16+ NK cells were found in the synovial tissue from patients with active RA, which induced an inflammatory, cytokine-secreting HLA-DR+CD90+ phenotype of synovial fibroblasts [150]. One study found that CD56+/CD16− cells were the major type in the osteoarthritic joint and were correlated with elevated inflammatory factors in SF [151]. Another study revealed that NK cells and neutrophils were the first cells accumulating in the synovium during experimental OA and were involved in the cartilage damage process [152].

Senescent human fibroblasts can be identified and killed by NK cells through NKG2D-NKG2D ligand interactions and degranulation of NK cells. NKG2D is expressed on CD4+CD28− T cells and NK cells. CD4+CD28− T cells rarely appear in healthy individual joint cavities, while these cells accumulate in RA and other autoimmune diseases [153]. RA synovial cells abnormally expressed the stress-inducible MIC ligands of NKG2D, which stimulated CD4+CD28− T cell cytokine production and proliferation [153]. However, the expression of Ra1 (a ligand of NKG2D in mice) is induced in all inflammatory joint diseases except collagenase-induced OA (CIOA) mouse models [154], which indicates that the NKG2D-NKG2D ligand interaction is absent in CIOA. It is unclear whether this interaction exists in other types of OA (Fig. 4).

NKG2A acts as an inhibitory receptor on immune cells, which interacts with MHC-I molecules and prevents our own cells from being killed [155]. The balance between activating receptors (such as NKG2D, DNAM-1, NKp44 and Nkp46) and inhibitory receptors (such as CD94/ NKG2A) determines the killing of senescent synovial cells by NK cells [156]. However, whether NKG2A functions in osteoarthritic joints remains unknown (Fig. 4).

NK cells are particularly suitable for immunotherapy due to their major histocompatibility complex (MHC) and antigen-independent manner [157]. However, the inherent immune clearance of senescent cells could sometimes be in vain due to the shedding of NKG2D ligands [158], low NKG2D ligand expression on senescent cells or low NKG2D expression in NK cells [159].

**Table 1** miRNAs involved in senescence or OA

| miRNAs         | Mainly target molecule or pathways                        | Effects                                                                 | References                      |
|----------------|-----------------------------------------------------------|------------------------------------------------------------------------|---------------------------------|
| miR-290        | CDK6, SIRT1, Sp1 mRNA                                      | Promotes senescence in mouse embryonic fibroblasts                     | Pitto et al. (2009) [146]       |
| miR-22         | p21 mRNA                                                  | Induces cellular senescence and suppresses tumour                      | Xu et al. (2011) [147]          |
| miR-302,       | IRAK4 mRNA                                                | Inhibits NF-κB pathways                                                | Afonina et al. (2017) [141]     |
| miR-512-3p     | Traf6 mRNA                                                | Inhibits NF-κB pathways                                                | O’Connell et al. (2012) [142]   |
| miR-515-3p     | SIRT1 mRNA                                                | Inhibits chondrocyte proliferation, promotes senescence and apoptosis   | Yan et al. (2016) [145]         |
| miR-204        | IGF1R and TLR4 in PI3K-AKT pathway and JAG1 and NUMBL in the Notch pathway | Inhibits proteoglycan (PG) biosynthesis                               | Kang et al. (2019) [144]        |
| miR-140        | IGF1R and TLR4 in PI3K-AKT pathway and JAG1 and NUMBL in the Notch pathway | Inhibits chondrocyte senescence and attenuates early OA development    | Si et al. (2020) [143]          |
| miR-126, miR-130a, miR-142, miR-21, miR-93 | Are associated with ageing | Are associated with ageing | Olivieri et al. (2017) [149] |
Some new immunotherapies may help. CD26/dipeptide peptidase 4 (DPP4) was identified as a senescence bio-
marker, and administration of anti-DPP4 antibody can induce ADCC, leading to the elimination of senescence
by NK cells [160]. Several DPP4 inhibitors, such as saxagliptin, teneligliptin and vildagliptin, can ameliorate
IL-1β or TNF-α-induced degradation of ECM and protect against chondrocyte senescence [161–163] (Fig. 4).

CAR-T cells or CAR-NK cells are another promising immunotherapy. A chimeric antigen receptor can redirect
T cells or NK cells to target specific factors. uPAR is upregulated in chondrocytes during OA and participates
in cartilage degradation [164]. In recent studies, urokinase-type plasminogen activator receptor (uPAR) was
found to be widely expressed on the senescent cell membrane, and uPAR-specific CAR-T cells were developed to
target senescence [165] (Fig. 4).

Many challenges need to be addressed. One limitation of cell therapy is the dense barrier of ECM in carti-
lage, which prevents immune cells from infiltrating and killing senescent cells. Moreover, OA is a disease with
strong heterogeneity and various aetiologies. It would
be complicated to identify the specific phenotype before using senolytics or cell therapy. Finally, screening and identifying an epitope of senescent cells in OA is critical. Only when these problems are resolved can immune cell therapy in OA become feasible.

Conclusions
Many SASP factors have long been known to be proinflammatory producers in the joint cavity or ECM degraders and degeneration catalysts. Several attempts have been made to neutralize the SASP but have not shown satisfactory outcomes in OA treatment. The senolytic drug UBX0101 failed to outperform the placebo in a phase II clinical trial. One possible reason for this failure to translate treatment into clinical use is the widely used 8-week-old mouse model rather than the aged mouse model which may reflect and guide application more robustly. Immunotherapy in OA is rather new and shows potential, as it is naturally in accordance with establishing normal homeostasis in old and young cells. Therapeutic molecular targets that can utilize the immune system need to be developed.

Abbreviations
OA: Osteoarthritis; RA: Rheumatoid arthritis; SASP: Senescence-associated secretory phenotype; PTOA: Posttraumatic osteoarthritis; NK cells: Natural killer cells; DDR: DNA damage response; ROS: Reactive oxygen species; MKK: Mitogen-activated protein kinase kinase; p38MAPK: P38 mitogen-activated protein kinase; IL-6: Interleukin-6; TGF-β: Transforming growth factor-β; PI3K: Phosphoinositide 3-kinase; CDK: Cyclin-dependent kinases; Rho: Retinoblas-toma protein; NF-κB: Nuclear factor kappa-B; mTOR: Mammalian target of rapamycin; CCL: Chemokine (C–C motif) ligand; MMP: Matrix metalloproteinase; TRPV4: Transient receptor potential vanilloid 4; FBXW7: F-box and WD domain repeat containing 7; MKK7: Mitogen-activated protein kinase kinase 7; JNK: Mitogen-activated protein kinase; Rac1: Ras-related C3 botulinum toxin substrate 1; VEGF2: Vascular endothelial growth factor 2; ECM: Extracellular matrix; ADAMTS5: A disintegrin and metalloproteinase with thrombospondin motifs 5; SF: Sfrp family; FLTN: Toll-like receptor 4; BMSCs: Bone marrow stem cells; mtDNA: Mitochondrial DNA; SOD2: Superoxide dismutase 2; BMI: Body mass index; TNF-α: Tumour necrosis factor-α; FFAs: Free fatty acids; SIRT: Sirtuin; HDACs: Histone deacetylases; NAD: Nicotinamide adenine dinucleotide; PAI-1: Plasminogen activator Inhibitor-1; PCSK9: Proprotein convertase subtilisin/kexin 9; AMPK: Adenosine 5′-monophosphate (AMP)-activated protein kinase; REDD1: DNA damage response 1; CMA: Chaperone-mediated autophagy; ATM: Ataxia telangiectasia mutated; ATR: Ataxia telangiectasia and RAD3-related protein; T-UTR: 3′-Untranslated region; IRAK4: Interleukin-1 receptor-associated kinase 4; TRAF6: TNF receptor-associated factor 6; PG: Proteoglycan; IGFR1: Insulin-like growth factor 1 receptor; ACLT: Anterior cruciate ligament associated kinase 4; TRAF6: TNF receptor-associated factor 6; P: Proteoglycan; IRS: Insulin-like growth factor 1 receptor; ACTL: Anterior cruciate ligament transaction; WOINAC: Western Ontario and McMaster Universities Osteoarthritis Index; ADCC: Antibody-dependent cell-mediated cytoxicity; DPP4: Dipeptidyl peptidase 4; CAR-T: Cell: Chimeric antigen receptor T cell; CAR-NK cell: Chimeric antigen receptor NK cell; NGK2D: Natural killer group 2, member D; HLA-E: Human leukocyte antigen-E; SLE: Systemic lupus erythematosus; CIOA: Collagenase-induced osteoarthritis; uPAR: Urokinase-type plasminogen activator receptor; SIRPA: Signal-regulatory protein alpha.

Acknowledgements
This manuscript was polished by Springer Nature Author Service.

Authors’ contributions
YL: data curation, investigation and writing—original draft; ZZ: software and visualization; TL: resources; HX: validation; HZ: writing — review and editing and supervision. The authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (NO. 81672197). Grant numbers: Y520,000.

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate
Not applicable.

Competing interests
The authors declare no competing interests.

Received: 3 April 2022   Accepted: 5 July 2022
Published online: 22 July 2022

References

1. Hunter DJ, Bijerma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745–59.
2. Martin JA, Brown TD, Heiner AD, Buckwalter JA. Chondrocyte senescence, joint loading and osteoarthritis. Clin Orthop Relat Res. 2004;427 Suppl:S96-103.
3. Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med. 2015;21(12):1424–35.
4. Childs BG, Gluscevic M, Baker DJ, Laberge RM, Marquess D, Danenberg J, et al. Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov. 2017;16(10):718–35.
5. Mobasheri A, Matta C, Zakany R, Musumeci G. Chondrosenescence: definition, hallmarks and potential role in the pathogenesis of osteoarthritis. Maturitas. 2015;80(3):237–44.
6. Chen X, Gong W, Shao X, Shi T, Zhang L, Dong J, et al. METTL3-mediated m6A modification of ATG7 regulates autophagy-GATA4 axis to promote cellular senescence and osteoarthritis progression. Ann Rheum Dis. 2022;81(1):87–99.
7. Guo Q, Chen X, Chen J, Zheng G, Xie C, Wu H, et al. STING promotes senescence, apoptosis, and extracellular matrix degradation in osteoarthritis via the NF-kappaB signaling pathway. Cell Death Dis. 2021;12(1):13.
8. Fu L, Hu Y, Song M, Liu Z, Zhang W, Yu FX, et al. Up-regulation of FOXD1 by YAP alleviates senescence and osteoarthritis. PLoS Biol. 2019;17(4):e3000201.
9. Duarte JH. Osteoarthritis: SIRT6 prevents chondrocyte senescence and DNA damage. Nat Rev Rheumatol. 2015;11(5):260.
10. Deng L, Ren R, Liu Z, Song M, Li J, Wu Z, et al. Stabilizing heterochromatin by DGC8 alleviates senescence and osteoarthritis. Nat Commun. 2019;10(1):3329.
11. Jeon OH, David N, Campisi J, Ellisseeff JH. Senescent cells and osteoarthritis: a painful connection. J Clin Invest. 2018;128(4):1229–37.
12. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013;21(4):16–21.
13. de Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJ, Zuurmond AM, Schoones J, Toes RE, et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthritis Cartilage. 2012;20(12):1484–99.
14. Scanzello CR. Role of low-grade inflammation in osteoarthritis. Curr Opin Rheumatol. 2017;29(1):79–85.
15. Wang Q, Roffele A, Lepus CM, Scanzello CR, Song J, Larsen DM, et al. Identification of a central role for complement in osteoarthritis. Nat Med. 2011;17(12):1674–9.
16. Jeon OH, Kim C, Laberge RM, Demaria M, Rathod S, Vassero AP, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med. 2017;23(6):775–81.

17. Xu M, Bradley EW, Weivoda MM, Hwang SM, Pirskalahva T, Decklever T, et al. Transplanted senescent cells induce an osteoarthritis-like condition in mice. J Gerontol A Biol Sci Med Sci. 2017;72(6):780–95.

18. Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, Zhong J, et al. Naturally occurring p16(ink4a)-positive cells confirm shortened healthy lifespan. Nature. 2016;530(7589):184–9.

19. Russian TJ, Azz A, Meyer CF, Swenson BL, van Deursen JM, Baker DJ. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018;562(7728):578–82.

20. Borkodina A, Shatrova A, Abushik P, Nikolsky N, Burova E. Interaction between ROS dependent DNA damage, mitochondria and p38 MAPK underlies senescence of human adult stem cells. Aging (Albany NY). 2018;10(6):481–91.

21. Munoz-Espin D, Serrano M. Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol. 2014;15(7):482–96.

22. Macip S, Igarashi M, Fang L, Chen A, Pan ZQ, Lee SW, et al. Inhibition of p21-mediated ROS accumulation can rescue p21-induced premature senescence. EMBO J. 2002;21(9):2180–8.

23. Lyu G, Guan Y, Zhang C, Zong L, Sun H, Huang X, et al. TGF-beta signaling alters SA-1 hemangioblast status via miR-29 and contributes to cellular senescence and cardiac aging. Nat Commun. 2018;9(1):2560.

24. Liu J, Liu Y, Chen H, Hu C, Teng M, Jiao K, et al. The ROS-mediated activation of IL-6/STAT3 signaling pathway is involved in the 27-hydroxysterol-induced cellular senescence in nerve cells. Toxicol In Vitro. 2017;45(Pt 1):1–10.

25. Kojima H, Kunitomo H, Inoue T, Nakajima K. The STAT3-IGFBP5 axis is underlies senescence of human adult stem cells. Aging Cell. 2018;17(4):e12771.

26. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, et al. A negative feedback signaling networks regulates the pro-tumorigenic senescence-associated secretory phenotype. EMBO J. 2002;21(9):2180–8.

27. Liu T, Zhang L, Joo D, Sun SC. NF-kappaB signaling in inflammation. Cell. 1997;88(5):593–602.

28. Freund A, Patil CK, Campisi J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype (SASP). Cell Cycle. 2012;11(4):730–9.

29. McConnell BB, Gregory FJ, Stott FJ, Hara E, Peters G. Induced expression of p16(ink4a) increases human cell senescence. Aging Cell. 2006;5(6):481–92.

30. Diekman BO, Sessions GA, Collins JA, Knecht AK, Strum SL, Mitin NK, et al. Tumor necrosis factor-alpha (TNF-alpha) enhances functional thermal and chemical responses of TRP cation channels in human synoviocytes. Mol Pain. 2009;5:49.

31. Denadai-Souza A, Martin I, de Paula MA, de Avellar MC, Muscara MN, Morgolle N, et al. Role of transient receptor potential vanilloid 4 in rat joint inflammation. Arthritis Rheum. 2012;64(9):2777–86.

32. Acosta JC, O’Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008;133(6):1006–18.

33. Nelson G, Wordsworth J, Wang C, Turk D, Lawless C, Martin-Ruiz C, et al. A senescent cell bystander effect. senescence-induced senescence. Aging Cell. 2012;11(2):345–9.

34. Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15(8):798–809.

35. Hoare M, Ito Y, Kang TW, Weekes MP, Matheson NJ, Patten DA, et al. NOITCHI mediates a switch between two distinct secretomes during senescence. Nat Cell Biol. 2016;18(9):979–92.

36. Zhang H, Shao Y, Yao Z, Liu L, Zhang H, Yin J, et al. Mechanical overloading promotes choreocyte senescence and osteoarthritis development through downregulating FBXW7. Ann Rheum Dis. 2022;81(5):676–86.

37. Loeser RF, Kelley KL, Armstrong A, Collins JA, Diekman BO, Carlson CS. Deletion of JNK enhances senescence in joint tissues and increases the severity of age-related osteoarthritis in mice. Arthritis Rheumatol. 2020;72(10):1679–88.

38. Takeda K, Machida T, Takezawa M, Takeuchi Y, Fujisawa T. The role of mechanical stresses in the pathogenesis of osteoarthritis: implications for treatment of joint injuries. Cartilage. 2013;4(4):286–94.

39. Swistone K, Murphy SE, Kefauver JM, Whitham T, Patapoutian A, Ward AB. Structure of the mechanically activated ion channel Piezo1. Nature. 2018;554(7693):481–6.

40. Wu J, Lewis AH, Grandi J. Touch, tension, and transduction - the function and regulation of Piezo ion channels. Trends Biochem Sci. 2017;42(1):57–71.

41. Liedtke W, Choe Y, Marti-Renoma MA, Bell AM, Denis CS, Sali A, et al. Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell. 2000;103(3):525–35.

42. Strotmann R, Harteneck C, Nunnennacker M, Schultz G, Plant TD. OTRPC4, a nonselective cation channel that confers sensitivity to extracellular osmolarity. Nat Cell Biol. 2000;2(10):695–702.

43. Phan MN, Leddy HA, Votta BJ, Kumar S, Levy DS, Lipshutz DB, et al. Functional characterization of TRPV4 as an osmotically sensitive ion channel in porcine articular chondrocytes. Arthritis Rheum. 2009;60(10):3028–37.

44. Agarwal P, Lee HP, Smeriglio P, Grandi G, Goodman S, Chaudhuri O, et al. A dysfunctional TRPV4-GSK3beta pathway prevents osteoarthritic chondrocytes from sensing changes in extracellular matrix viscoelasticity. Nat Biomed Eng. 2021;5(12):1472–84.

45. Xu B, Xing R, Huang Z, Yin S, Li X, Zhang L, et al. Excessive mechanical stress induces choreocyte apoptosis through TRPV4 in an anterior cruciate ligament-ruptured rat osteoarthritis model. Life Sci. 2019;228:158–66.

46. Kochukov MY, McNeary TA, Yin H, Zhang L, Ma F, Ponomareva L, et al. Tumor necrosis factor-alpha (TNF-alpha) enhances functional thermal and chemical responses of TRP cation channels in human synoviocytes. Mol Pain. 2009;5:49.

47. Denadai-Souza A, Martin I, de Paula MA, de Avellar MC, Muscara MN, Morgolle N, et al. Role of transient receptor potential vanilloid 4 in rat joint inflammation. Arthritis Rheum. 2012;64(9):2777–86.
60. De Ceuninck F, Dassencourt L, Anract P. The inflammatory side of human chondrocytes unveiled by antibody microarrays. Biochem Biophys Res Commun. 2004;323(3):960–9.

61. Clutterbuck AL, Smith JR, Allaway D, Harris P, Liddell S, Mobasher A. High throughput proteomic analysis of the secretome in an explant model of articular cartilage inflammation. J Proteomics. 2011;74(5):704–15.

62. Li WQ, Dehnade F, Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol. 2001;166(5):3491–8.

63. Coryell PR, Diekman BO, Loeser RF. Mechanisms and therapeutic implications of cellular senescence in osteoarthritis. Nat Rev Rheumatol. 2021;17(1):47–57.

64. Chou CH, Jain V, Gibson J, Attarian DE, Haraden CA, Yohn CB, et al. Synovial cell cross-talk with cartilage plays a major role in the pathogenesis of osteoarthritis. Sci Rep. 2020;10(1):10866.

65. Barreto G, Senturk B, Colombo L, Bruck O, Neidenbach P, Salzmann G, et al. Lumican is upregulated in osteoarthritis and contributes to TLR4-induced pro-inflammatory activation of cartilage degradation and macrophage polarization. Osteoarthrit Cartilage. 2020;28(1):92–101.

66. Cao X, Luo P, Huang J, Li C, He J, Wang Z, et al. Intrarticular senescent chondrocytes impair the cartilage regeneration capacity of mesenchymal stem cells. Stem Cell Res Ther. 2019;10(1):146.

67. Loeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(7):412–20.

68. Passos JF, Saretzki G, von Zglinicki T. DNA damage in telomeres and mitochondrial function during cellular senescence: is there a connection? Nucleic Acids Res. 2007;35(22):7505–13.

69. Gristho V, Ho R, Wilson GL, Pearsall AW, Diminished mitochondrial DNA integrity and repair capacity in OA chondrocytes. Osteoarthrit Cartilage. 2009;17(1):107–13.

70. Almeida M, O'Brien CA. Basic biology of skeletal aging: role and targets in osteoarthritis. Biochim Biophys Acta. 2016;1862(4):576–91.

71. Mobasher A, Rayman MP, Guallilo O, Sellam J, van der Kraan P, Fearon U. The role of metabolism in the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2017;13(5):302–11.

72. Wang T, He C. Pro-inflammatory cytokines: the link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018;44:38–50.

73. Wang X, Hunter D, Xu J, Ding C. Metabolic triggered inflammation in osteoarthritis. Osteoarthrit Cartilage. 2015;23(1):22–30.

74. Grote M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up. BMC Musculoskelet Disord. 2008;9:132.

75. Dickson BM, Roeslof AJ, Rochford JJ, Wilson HM, De Bari C. The burden of metabolic syndrome on osteoarticular joint health. Arthritis Res Ther. 2019;21(1):289.

76. Medina-Luna D, Santamaría-Olmedo MG, Zamudio-Cuevas Y, Martinez-Flores K, Fernández-Torres J, Martínez-Nava GA, et al. Hyperlipidemic microenvironment conditionates damage mechanisms in human chondrocytes by oxidative stress. Lipids Health Dis. 2017;16(1):14.

77. Koskinen A, Vuolteenaho N, Nieminen R, Moilanen T, Moilanen E. Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients. Clin Exp Rheumatol. 2011;29(1):57–64.

78. Zhao X, Dong Y, Zhang J, Li D, Hu G, Yao J, et al. Leptin changes differentiation fate and cell senescence in chondrogenic progenitor cells. Cell Death Dis. 2016;7:e2188.

79. Morris BJ. Seven sirtuins for seven deadly diseases of aging. Free Radic Biol Med. 2013;56:133–71.

80. Julien C, Tremblay C, Ermond V, Lebbad M, Salem N Jr, Bennett DA, et al. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol. 2009;68(1):48–58.

81. Pulla VK, Battu MB, Alvala M, Siritanvorawot D. Can targeting SIRT-1 to treat type 2 diabetes be a good strategy? A review. Expert Opin Ther Targets. 2012;16(8):819–32.

82. Chen C, Zhou M, Ge Y, Wang X. SIRT1 and aging related signaling pathways. Mech Ageing Dev. 2020;187:111215.

83. Wang T, Wang Y, Liu L, Jiang Z, Li X, Tong R, et al. Research progress on sirtuins family members and cell senescence. Eur J Med Chem. 2020;193:11207.

84. Dvir-Ginzberg M, Mobasher A, Kumar A. The role of sirtuins in cartilage homeostasis and osteoarthritis. Curr Rheumatol Rep. 2016;18(7):43.

85. Dudev M, Gossan N, Yang N, Im HJ, Ruckshanthi JP, Yoshitane H, et al. The chondrocyte clock gene Bmal1 controls cartilage homeostasis and integrity. J Clin Invest. 2016;126(1):365–76.

86. Matsuzaki T, Matsuishi T, Takayama K, Matsumoto T, Nishida K, Kuroda R, et al. Disruption of Sirt1 in chondrocytes causes accelerated progression of osteoarthritis under mechanical stress and during aging in mice. Ann Rheum Dis. 2014;73(7):1397–404.

87. Dvir-Ginzberg M, Gagavina V, Lee EI, Hall DJ. Regulation of cartilage-specific gene expression in human chondrocytes by Sirt1 and nicotinamide phosphoribosyltransferase. J Biol Chem. 2008;283(52):36200–10.

88. Batson G, Elayyan J, Qiq Q, Reich E, Ben-Aderet L, Kandel L, et al. Serum NT/C/T SIRT1 ratio reflects early osteoarthritis and chondrosenescence. Ann Rheum Dis. 2020;79(10):1370–80.

89. Yang W, Kang X, Liu J, Li H, Ma Z, Jin X, et al. Clock gene Bmal1 modulates human cartilage gene expression by crosstalk with Sirt1. Endocrinology. 2016;157(8):3096–107.

90. He Y, Wu Z, Xu L, Xu K, Chen Z, Ran J, et al. The role of SIRT3-mediated mitochondrial homeostasis in osteoarthritis. Cell Mol Life Sci. 2020;77(19):3729–43.

91. Fu Y, Kinter M, Hudson J, Humphries KM, Lane RS, White JR, et al. Aging promotes SirT3-dependent cartilage superoxide dismutase 2 acetylation and osteoarthritis. Arthritis Rheumatol. 2016;68(8):1887–98.

92. Nagaï K, Matsushita T, Matsuzaki T, Takayama K, Matsumoto T, Kuroda R, et al. Depletion of Sirt6 causes cellular senescence, DNA damage, and telomere dysfunction in human chondrocytes. Osteoarthrit Cartilage. 2015;23(8):1412–20.

93. Wu Y, Chen L, Wang Y, Li W, Lin Y, Yu D, et al. Overexpression of Sirt6 suppresses cellular senescence and NF-kappaB mediated inflammatory responses in osteoarthritis development. Sci Rep. 2015;5:17602.

94. Blaney Davidson EN, van Caam AP, van der Kraan PM. Osteoarthritis year in review 2016: biology. Osteoarthrit Cartilage. 2017;25(2):175–80.
106. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27–42.
107. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40(2):280–93.
108. Carames B, Taniguchi N, Otsuki S, Blanco FI, Lotz M. Autophagy is a protective mechanism in normal cartilage, and its aged-related loss is linked with cell death and osteoarthritis. Arthritis Rheum. 2010;62(3):791–801.
109. Carames B, Olmer M, Kiosses WB, Lotz MK. The relationship of autophagy defects to cartilage damage during joint aging in a mouse model. Arthritis Rheumatol. 2015;67(6):1568–76.
110. Alvarez-Garcia O, Matsutsuki T, Olmer M, Plate L, Kelly JW, Lotz MK. Regulated in development and DNA damage response 1 deficiency impairs autophagy and mitochondrial biogenesis in articular cartilage and increases the severity of experimental osteoarthritis. Arthritis Rheumatol. 2017;69(7):1418–28.
111. Chang J, Wang W, Zhang H, Hu Y, Wang M, Yin Z. The dual role of autophagy in chondrocyte responses in the pathogenesis of articular cartilage degeneration in osteoarthritis. Int J Mol Med. 2013;32(6):1311–8.
112. Moreno-Blas D, Gorostienda-Salas E, Castro-Obregon S. Connecting chaperone-mediated autophagy dysfunction to cellular senescence. Ageing Res Rev. 2018;41:34–41.
113. Kang C, Xu Q, Martin TD, Li MZ, Demaria M, Aizenman DE, et al. The DNA damage response regulates inflammation and senescence by inhibiting autophagy of GATA4. Science. 2015;349(6255):aaa5612.
114. Kang C, Eldidge SJ. How autophagy both activates and inhibits cellular senescence. Autophagy. 2016;12(5):898–9.
115. Bernard M, Yang B, Migoneault F, Turgeon J, Dieude M, Olivier MA, et al. Autophagy drives fibroblast senescence through MTORC2 regulation. Autophagy. 2020;16(1):2004–16.
116. Xu M, Pirskhalava T, Farr JN, Pirtskhalava T, Palmer AK, Weivoda MM, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246–56.
117. Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu N, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18–28.
118. Zhu Y, Tchkonia T, Fuhrmann-Stroissnigg H, Dai HM, Ling YY, Stout MB, et al. Quercetin alleviates rat osteoarthritis development and progression through activation of AMPK signaling. Osteoarthritis Cartilage. 2017;25(10):1708–18.
119. Jotanovic Z, Mihelic R, Sestan B, Dembic Z. Role of interleukin-1 in the pathogenesis of osteoarthritis in mice. Arthritis Rheumatol. 2017;69(7):1418–28.
120. Krzyski P, Buckland-Wright C, Balint G, Cline GA, Stoner K, Lyon R, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther. 2007;9(5):R109.
121. Raychaudhuri SP, Raychaudhuri SK. Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis Res Ther. 2017;19(1):51.
122. Faust HJ, Zhang H, Han J, Wolf MT, Leonhardt A, Stadelmann C, et al. IL-17A and interleukin-17C induce chondrocyte apoptosis and proliferation by targeting the SIRT1/p53 signaling pathway during the pathogenesis of osteoarthritis. Arthritis Rheumatol. 2017;69(7):1418–28.
123. Liu et al. Arthritis Research & Therapy 2022 24:174
124. Borgdorff V, Leonart ME, Bishop CL, Fessart D, Bergin AH, Overhoff MG, et al. Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21(Waf1/Cip1). Oncogene. 2010;29(15):2262–71.
125. Olivieri F, Capri M, Bonafe M, et al. Circulating miRNAs rescue from Ras-induced senescence by inhibiting p21(Waf1/Cip1). Oncogene. 2010;29(15):2262–71.
126. Calcinotto A, Kohli J, Zagozlo M, Pellegrini L, Demaria M, Alimonti A. Cellular senescence: ageing, cancer, and injury. Physiol Rev. 2019;99(2):1047–78.
127. Fane M, Weeraratna AT. How the ageing microenvironment influences tumour progression. Nat Rev Cancer. 2020;20(2):89–106.
128. van Deursen JM. The role of senescent cells in ageing. Nature. 2014;509(7541):439–46.
129. Si HB, Yang TM, Li L, Tian M, Zhou L, Li DP, et al. miR-140 attenuates the progression of early-stage osteoarthritis by retarding chondrocyte senescence. Mol Ther Nucleic Acids. 2020;21(1):275–91.
130. Xu O, Tahara H. The role of exosomes and microRNAs in senescence and aging. Adv Drug Deliv Rev. 2013;65(3):368–75.
131. Bu H, Wedel S, Caviniato M, Jansen-Durr P. MicroRNA regulation of oxidative stress-induced cellular senescence. Oxd Med Cell Longev. 2017;2017:2398696.
132. Li J, Zhang B, Liu WX, Lu K, Pan H, Wang T, et al. Metformin limits osteoarthritis development and progression through activation of AMPK signalling. Ann Rheum Dis. 2020;79(5):635–45.
133. Guo H, Ding D, Wang L, Yan J, Ma L, Jin Q. Metformin attenuates osteoclast-mediated abnormal subchondral bone remodeling and alleviates osteoarthritis via AMPK/NF-kappaB/ERK signaling pathway. PLoS One. 2021;16(12):e0261127.
134. Na HS, Kwon JY, Lee SY, Lee SH, Lee AR, Woo JS, et al. Metformin attenuates monosodium-iiodacetate-induced osteoarthritis via regulation of pain mediators and the autophagy-lysosomal pathway. Cells. 2021;10(3):681.
135. Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell. 2014;31(6):722–33.
136. Yun MH. Cellular senescence in tissue repair: every cloud has a silver lining. Int J Dev Biol. 2018;62(6–7):891–904.
137. Majidinia M, Mir SM, Mirza-Aghadhezh-Attari M, Asghari R, Kafsi HS, Safa A, et al. MicroRNAs, DNA damage response and ageing. Biogerontology. 2020;21(3):275–91.
138. Kang D, Shin J, Cho Y, Kim HS, Gu YR, Kim H, et al. Stress-activated miR-204 governs senescence phenotypes of chondrocytes to promote osteoarthritis development. Sci Transl Med. 2019;11(486):eaar6659.
139. Yan S, Wang M, Zhao J, Zhang H, Zhou C, Jin L, et al. MicroRNA-34a affects chondrocyte apoptosis and proliferation by targeting the SIRT1/p53 signaling pathway during the pathogenesis of osteoarthritis. Int J Mol Med. 2016;38(1):201–9.
140. Pittro L, Rizzo M, Simili M, Collignani D, Evangelista M, Mercantanti A, et al. miR-290 acts as a physiological effector of senescence in mouse embryo fibroblasts. Physiol Genomics. 2009;39(3):210–8.
141. Afonina IS, Zhong Z, Karin M, Beyaert R. Limiting inflammation—The negative regulation of NF-kappaB and the NLRP3 inflammasome. Nat Immunol. 2017;18(8):861–9.
142. O’Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annu Rev Immunol. 2012;30:295–312.
143. Si HB, Yang TM, Li L, Tian M, Zhou L, Li DP, et al. miR-140 attenuates the progression of early-stage osteoarthritis by retarding chondrocyte senescence. Mol Ther Nucleic Acids. 2020;19:15–30.
144. Kang D, Shin J, Cho Y, Kim HS, Gu YR, Kim H, et al. Stress-activated miR-204 governs senescence phenotypes of chondrocytes to promote osteoarthritis development. Sci Transl Med. 2019;11(486):eaar6659.
145. Majidinia M, Mir SM, Mirza-Aghadhezh-Attari M, Asghari R, Kafsi HS, Safa A, et al. MicroRNAs, DNA damage response and ageing. Biogerontology. 2020;21(3):275–91.
146. Majidinia M, Mir SM, Mirza-Aghadhezh-Attari M, Asghari R, Kafsi HS, Safa A, et al. MicroRNAs, DNA damage response and ageing. Biogerontology. 2020;21(3):275–91.
152. Benigni G, Dimitrova P, Antonangeli F, Sansevero E, Milanova V, Blom A, et al. CXCR3/CXCL10 axis regulates neutrophil-NK cell cross-talk determining the severity of experimental osteoarthritis. J Immunol. 2017;198(5):2115–24.

153. Groh V, Bruhl A, El-Gabalawy Y, Nelson JL, Spies T. Stimulation of T cell auto-reactivity by anomalous expression of NKG2D and its MHC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2003;100(16):9452–7.

154. Mariotte A, Bernardi L, Macquin C, DeCauwer A, Kotova I, Bluml S, et al. NKG2D ligands in inflammatory joint diseases: analysis in human samples and mouse models. Clin Exp Rheumatol. 2021;39(5):982–7.

155. Brooks AG, Posch PE, Scorzelli G, Borrego F, Coligan JE. NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J Exp Med. 1997;185(4):795–800.

156. Nielsen N, Pascal V, Fasth AE, Sundstrom Y, Galsgaard ED, Ahern D, et al. Balance between activating NKG2D, DNAM-1, Nkp44 and Nkp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts. Immunology. 2014;142(4):581–93.

157. Sordo-Bahamonde C, Vitale M, Lorenzo-Herrero S, Lopez-Soto A, Gonzalez S. Mechanisms of resistance to NK cell immunotherapy. Cancers (Basel). 2020;12(4):893.

158. Dhar P, Wu JD. NKG2D and its ligands in cancer. Curr Opin Immunol. 2018;51:55–61.

159. Munoz DP, Yannone SM, Daemen A, Sun Y, Vakar-Lopez F, Kawahara M, et al. Targetable mechanisms driving immune evasion of persistent senescent cells link chemotherapy-resistant cancer to aging. JCI Insight. 2019;5(14):e124716.

160. Kim KM, Noh JH, Bodogai M, Martindale JL, Yang X, Indig FE, et al. Identification of senescent cell surface targetable protein DPP4. Genes Dev. 2017;31(15):1529–34.

161. Bi J, Cai W, Ma T, Deng A, Ma P, Han Y, et al. Protective effect of vildagliptin on TNF-alpha-induced chondrocyte senescence. JUBMB Life. 2019;71(7):978–85.

162. Hu N, Gong X, Yin S, Li Q, Chen H, Li Y, et al. Saxagliptin suppresses degradation of type II collagen and aggrecan in primary human chondrocytes: a therapeutic implication in osteoarthritis. Artif Cells Nanomed Biotechnol. 2019;47(1):3239–45.

163. Gao F, Wang Y, Wu M. Teneligliptin inhibits IL-1beta-induced degradation of extracellular matrix in human chondrocytes. J Cell Biochem. 2020;121(1):4450–7.

164. Schub W, Schulze-Tanzil G, Mehtasheri A, Dressler J, Kotzsch M, Shakiabi M. Interleukin-1beta-induced expression of the urokinase-type plasminogen activator receptor and its co-localization with MMPs in human articular chondrocytes. Histol Histopathol. 2004;19(1):105–12.

165. Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, et al. Senolytic CART cells reverse senescence-associated pathologies. Nature. 2020;583(7814):127–32.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.